Stereotactic body radiation therapy and intensity modulated radiation therapy induce different plasmatic cytokine changes in non-small cell lung cancer patients: a pilot study

Clinical and Translational Oncology

Volumn 18, Issue 10, 2016, Pages 1003-1010

  Trovo, M ^a   Giaj Levra, N ^b,c   Furlan, C ^a   Bortolin, M T ^a   Muraro, E ^a   Polesel, J ^a   Minatel, E ^a   Tedeschi, R ^a   Filippi, A R ^c   Alongi, F ^b   Ricardi, U ^c  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Cytokines; Intensity modulated radiotherapy; Non small cell lung cancer; Stereotactic ablative radiotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN RECEPTOR; CYTOKINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HUMAN; IMMUNE RESPONSE; INTENSITY MODULATED RADIATION THERAPY; MALE; NON SMALL CELL LUNG CANCER; PILOT STUDY; PROSPECTIVE STUDY; STEREOTACTIC BODY RADIATION THERAPY; ADENOCARCINOMA; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; ENZYME IMMUNOASSAY; FOLLOW UP; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; RADIOSURGERY; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84986575529     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1473-x     Document Type: Article

References (49)

1. Bradley JD, El Naqua I, Drzymala RE, Trovò M, Jones G, Denning MD. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: the pattern of failure is distant. Int J Radiat Oncol Biol Phys. 2010;77:1146–50.
2. National Comprehensive Cancer Network. 2015. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 24 Nov 2015.
3. Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.
4. Curran W, Paulus R, Langer C, Komaki R, Lee JD, Hauser S, et al. Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103:1452–60.
5. Bearz A, Minatel E, Rumeileh IA, et al. Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: a phase I, docetaxel dose-escalation study, with hypofractionated radiation regimen. BMC Cancer. 2013;13:513.
6. Faivre-Finn C. Dose escalation in lung cancer: have we gone full circle? Lancet Oncol. 2015;16:125–7.
7. Trovo M, Linda A, El Naqua I, Javidan-Nejad C, Bradley J. Early and late radiographic injurie following stereotactic body radiation therapy (SBRT). Lung Cancer. 2010;69:77–85.
8. Linda A, Trovo M, Bradley JD. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes. Eur J Radiol. 2011;79:147–54.
9. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, et al. A sense of danger from radiation. Radiat Res. 2004;162:1–19.
10. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment—tumorigenesis and therapy. Nat Rev Cancer. 2005;5:867–75.
11. Rübe CE, Wilfert F, Uthe D, König J, Liu L, Schuck A, et al. Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. Radiother Oncol. 2004;72:231–41.
12. Chen Y, Williams J, Ding I, Hernady E, Liu W, Smudzin T, et al. Radiation pneumonitis and early circulatory cytokine markers. Semin Radiat Oncol. 2002;12(1 suppl 1):26–33.
13. Hong ZY, Song KH, Yoon JH, Cho J, Story MD. An experimental model-based exploration of cytokines in ablative radiation-induced lung injury in vivo and in vitro. Lung. 2015;193:409–19.
14. Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, et al. The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Am J Respir Cell Mol Biol. 2011;45:127–35.
15. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359(9315):1388–93.
16. Ansher MS, Kong FM, Andrews K, Clough R, Marks LB, Bentel G, et al. Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 1998;41:1029–35.
17. Ansher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, et al. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:988–95.
18. Chen Y, Rubin P, William J, Hernady E, Smudzin T, Okunieff P. Circulating IL-6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2001;49:641–8.
19. Bright RK. Immunology of lung cancer. In: Pass HI, Mitchel IB, Johnson DH, et al., editors. Lung cancer. Philadelphia: Lippincott W&W; 2000. p. 304–18.
20. Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res. 2006;130:125–40.
21. Travès PG, Luque A, Hortelano S. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm. 2012;2012:568783.
22. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. Lung Cancer. 1996;16:47–59.
23. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity. 2014;41(5):830–42.
24. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med. 2011;208(10):2005–16.
25. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41(5):843–52.
26. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28.
27. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer. 2010;69:348–54.
28. Fleckenstein K, Gauter-Fleckenstein B, Jackson IL, Rabbani Z, Anscher M, Vujaskovic Z. Using biological markers to predict risk of radiation injury. Semin Radiat Oncol. 2007;17:89–98.
29. Han G, Zhang H, Xie CH, Zhou YF. Th2-like immune response in radiation-induced lung fibrosis. Oncol Rep. 2011;26:383–8.
30. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18:1028–40.
31. Zeng L, O’Connor C, Zhang J, Kaplan AM, Cohen DA. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine. 2010;49:294–302.
32. De Vita F, Orditura M, Galizia G, Ciaramella F, Musicò M, Ferrigno A, et al. Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest. 2000;117:365–73.
33. Mocellin S. The dual role of IL-10. Trends Immunol. 2003;24:36–43.
34. Wang YC, Sung WW, Wu TC, Wang L, Chien WP, Cheng YW, et al. Interleukin-10 haplotype may predict survival and relapse in resected non-small cell lung cancer. PLoS One. 2012;7:e39525.
35. Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, et al. Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. J Clin Oncol. 2005;23:8748–56.
36. Neurath MF, Finotto S. The emerging role of T cell cytokines in non-small cell lung cancer. Cytokine Growth Factor Rev. 2012;23:315–22.
37. Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu YM, et al. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther. 2011;12:610–6.
38. Crittenden M, Gough M, Harrington K, Olivier K, Thompson J, Vile RG. Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res. 2003;63:5505–12.
39. Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets. 2012;12:107–23.
40. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer. 2000;89:484–7.
41. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;3:323–40.
42. Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control. 2008;15:140–50.
43. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy induced immunogenic cell death. Oncoimmunology. 2014;3:e28518.
44. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol. 2012;2:153.
45. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95.
46. Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24(5):589–602.
47. Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177(3):311–27.
48. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer. 2002;87:21–7.
49. Heuvers ME, Aerts JG, Cornelissen R, Groen H, Hoogsteden HC, Hegmans JP. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer. 2012;12:580.